| Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A (NCT06136507) | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 2026-12-25 |
| Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment. (NCT07684898) | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 2026-06-12 |
| Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment (NCT07663903) | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 2026-04-14 |
| Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (NCT06142552) | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 2023-12-27 |
| SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment (NCT06010953) | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 2023-10-12 |
| A Phase I of SS109 in Hemophilia A or and B With Inhibitors (NCT05651061) | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 2022-12-14 |
| A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (NCT05265286) | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 2022-04-14 |
| A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (NCT04864743) | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 2021-06-22 |
| A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII ，Fc Fusion Protein for Injection (NCT05251090) | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | 2021-06-16 |